We invest in Europe's tech leaders at Series A and beyond to make more possible. More from hardware, more from software, more from healthcare, more for consumers... the hardest tech problems are just the biggest business opportunities.
Molten Ventures has led an oversubscribed Series A funding round of $12 million in Anima, the next generation care enablement platform. Anima’s operating system for clinics resolves 85% of patient inquiries within 24 hours.
Today Molten is delighted to announce that we have completed our acquisition of Forward Partners, a proposition we announced in November last year.
IMU Biosciences secures £11.5 million in Series A funding to revolutionise immune powered precision medicine.
Molten Ventures today announces that it has led a Series B funding round of $16.5m in Morressier.
We can now announce that we have successfully raised £55m. This capital will help Molten back some of Europe’s most exciting, high growth technology companies.
We are pleased to announce that the Boards of Molten Ventures and Forward Partners have agreed on the terms of a recommended all-share acquisition of Forward Partners by Molten Ventures, subject to regulatory approvals.
